Your browser doesn't support javascript.
loading
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
Yang, David D; Muralidhar, Vinayak; Mahal, Brandon A; Labe, Shelby A; Nezolosky, Michelle D; Vastola, Marie E; King, Martin T; Martin, Neil E; Orio, Peter F; Choueiri, Toni K; Trinh, Quoc-Dien; Spratt, Daniel E; Hoffman, Karen E; Feng, Felix Y; Nguyen, Paul L.
Afiliação
  • Yang DD; Harvard Medical School, Boston, Massachusetts.
  • Muralidhar V; Department of Medicine, Harvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Mahal BA; Harvard Radiation Oncology Program, Boston, Massachusetts.
  • Labe SA; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Nezolosky MD; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Vastola ME; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • King MT; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Martin NE; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Orio PF; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Choueiri TK; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Trinh QD; Division of Urological Surgery, Harvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
  • Spratt DE; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; University of Michigan, Ann Arbor, Michigan.
  • Hoffman KE; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Feng FY; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Departments of Urology & Medicine and Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
  • Nguyen PL; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: Paul_Nguyen@dfci.harvard.edu.
Int J Radiat Oncol Biol Phys ; 98(2): 338-343, 2017 06 01.
Article em En | MEDLINE | ID: mdl-28463152

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antagonistas de Androgênios Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antagonistas de Androgênios Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2017 Tipo de documento: Article